New approaches to molecular monitoring in CML (and other diseases)
Chronic myeloid leukemia (CML) is the model cancer, demonstrating the clinical benefits of
targeted therapy and the power of molecular diagnostics and monitoring. In CML, the BCR …
targeted therapy and the power of molecular diagnostics and monitoring. In CML, the BCR …
The Present and Future Landscapes of Molecular Diagnostics
JC Rolando, AV Melkonian… - Annual Review of …, 2024 - annualreviews.org
Nucleic acid testing is the cornerstone of modern molecular diagnostics. This review
describes the current status and future directions of molecular diagnostics, focusing on four …
describes the current status and future directions of molecular diagnostics, focusing on four …
Droplet digital PCR for BCR/ABL (P210) detection of chronic myeloid leukemia: A high sensitive method of the minimal residual disease and disease progression
WJ Wang, CF Zheng, Z Liu, YH Tan… - European journal of …, 2018 - Wiley Online Library
Objective This study intended to establish a droplet digital PCR (dd‐PCR) for monitoring
minimal residual disease (MRD) in patients with BCR/ABL (P210)‐positive chronic myeloid …
minimal residual disease (MRD) in patients with BCR/ABL (P210)‐positive chronic myeloid …
Performance characteristics of the first Food and Drug Administration (FDA)-cleared digital droplet PCR (ddPCR) assay for BCR::ABL1 monitoring in chronic …
DN Shelton, P Bhagavatula, N Sepulveda, L Beppu… - PLoS …, 2022 - journals.plos.org
Chronic myelogenous leukemia (CML) is a hematopoietic stem cell malignancy that
accounts for 15–20% of all cases of leukemia. CML is caused by a translocation between …
accounts for 15–20% of all cases of leukemia. CML is caused by a translocation between …
Precision medicine in low-and middle-income countries
JP Radich, E Briercheck, DT Chiu… - Annual Review of …, 2022 - annualreviews.org
Most cancer cases occur in low-and middle-income countries (LMICs). The sophisticated
technical and human infrastructure needed for optimal diagnosis, treatment, and monitoring …
technical and human infrastructure needed for optimal diagnosis, treatment, and monitoring …
Definition, epidemiology, pathophysiology, and essential criteria for diagnosis of pediatric chronic myeloid leukemia
M Suttorp, F Millot, S Sembill, H Deutsch, M Metzler - Cancers, 2021 - mdpi.com
Simple Summary The low incidence (1: 1,000,000) of chronic myeloid leukemia (CML) in the
first two decades of life presents an obstacle to accumulation of pediatric experience and …
first two decades of life presents an obstacle to accumulation of pediatric experience and …
Measurement of BCR-ABL1 transcripts on the International Scale in the United States: current status and best practices
R Arora, RD Press - Leukemia & Lymphoma, 2017 - Taylor & Francis
Chronic myeloid leukemia (CML) results from the Philadelphia chromosome (Ph)
translocation and expression of its fusion oncoprotein BCR-ABL1. BCR-ABL1 tyrosine …
translocation and expression of its fusion oncoprotein BCR-ABL1. BCR-ABL1 tyrosine …
Molecular monitoring of chronic myeloid leukemia: present and future
ABSTRACT Introduction: Fusion of BCR-ABL1 genes causes chronic myeloid leukemia
(CML). As a reliable marker of disease burden, it also serves as the target of tyrosine kinase …
(CML). As a reliable marker of disease burden, it also serves as the target of tyrosine kinase …
A simple fluorescence biosensing strategy for ultrasensitive detection of the BCR–ABL1 fusion gene based on a DNA machine and multiple primer-like rolling circle …
H Wu, X Zhou, W Cheng, T Yuan, M Zhao, X Duan… - Analyst, 2018 - pubs.rsc.org
A one-step, rapid fluorescence biosensing method has been developed for ultrasensitive
detection of the BCR–ABL1 fusion gene based on a polymerase/nicking endonuclease DNA …
detection of the BCR–ABL1 fusion gene based on a polymerase/nicking endonuclease DNA …
Molecular genetic evaluation of myeloproliferative neoplasms
EM Azzato, A Bagg - International journal of laboratory …, 2015 - Wiley Online Library
The classical myeloproliferative neoplasms (MPN s) consist of chronic myelogenous
leukemia (CML) and the non‐CML MPN s, polycythemia vera (PV), essential …
leukemia (CML) and the non‐CML MPN s, polycythemia vera (PV), essential …